In a double blind, placebo controlled, cross over study the correlations between single doses (2, 4, and 8 mg), plasma concentrations, and antispastic action of tizanidine were investigated in 16 patients with extensor spasticity of the legs due to multiple sclerosis. An electrogoniometer was used to assess muscle tone at knee extensors, applying Wartenberg Further statistical analysis showed a strong within patient linear correlation between plasma concentrations and antispastic action at 4 and 8 mg doses (p = 0-014 and 0'004 respectively), but only weak between patient correlations. The analysis of the dose-plasma concentration relation showed results consistent with linear pharmacokinetics. The comparison of changes in the R2 ratio with concomitant Ashworth scores showed a significant correlation between the two. It is concluded that there are linear correlations between single doses, plasma concentrations, and antispastic action of tizanidine. Because of the strong within patient but weak between patient correlation between plasma concentrations and antispastic action of tizanidine the effective doses should be determined individually. (9 Neurol Neurosurg Psychiatry 1994;57: 1355-1359 Tizanidine (SirdaludO) is a centrally active a, adrenergic receptor agonist with potent myotonolytic action.l The substance was shown to suppress selectively polysynaptic spinal reflexes while sparing the monosynaptic reflexes.5 Clinical investigations have consistently shown an antispastic effect of tizanidine that was associated with little undue muscle weakness,69 sometimes associated with an improvement in paresis.10 There is, however, little information on the correlation between the antispastic effect and plasma concentrations of tizanidine. ' We report data on the correlations between single doses, plasma concentrations, and antispastic action of tizanidine in patients with spasticity due to multiple sclerosis, by means of an objective quantitative method and a clinical scale for the assessment of spasticity.
M Emre, G C Leslie, C Muir, N J Part, R Pokorny, R C Roberts Abstract In a double blind, placebo controlled, cross over study the correlations between single doses (2, 4, and 8 mg), plasma concentrations, and antispastic action of tizanidine were investigated in 16 patients with extensor spasticity of the legs due to multiple sclerosis. An electrogoniometer was used to assess muscle tone at knee extensors, applying Wartenberg' s pendulum test. Blood samples, a clinical assessment of muscle tone by the Ashworth scale, and muscle strength by the British Medical Research Council scale were obtained concomitandy. Confirmatory analysis using the change in the relaxation index (R2 value) 1.5 hours after each treatment, showed a statistically significant (p = 0.0123) linear dose-response relation between single doses and antispastic action of tizanidine. Further statistical analysis showed a strong within patient linear correlation between plasma concentrations and antispastic action at 4 and 8 mg doses (p = 0-014 and 0'004 respectively), but only weak between patient correlations. The analysis of the dose-plasma concentration relation showed results consistent with linear pharmacokinetics. The comparison of changes in the R2 ratio with concomitant Ashworth scores showed a significant correlation between the two. It is concluded that there are linear correlations between single doses, plasma concentrations, and antispastic action of tizanidine. Because of the strong within patient but weak between patient correlation between plasma concentrations and antispastic action of tizanidine the effective doses should be determined individually. (9 Neurol Neurosurg Psychiatry 1994; 57: 1355 -1359 Tizanidine (SirdaludO) is a centrally active a, adrenergic receptor agonist with potent myotonolytic action.l The substance was shown to suppress selectively polysynaptic spinal reflexes while sparing the monosynaptic reflexes.5 Clinical investigations have consistently shown an antispastic effect of tizanidine that was associated with little undue muscle weakness,69 sometimes associated with an improvement in paresis.10 There is, however, little information on the correlation between the antispastic effect and plasma concentrations of tizanidine. ' We report data on the correlations between single doses, plasma concentrations, and antispastic action of tizanidine in patients with spasticity due to multiple sclerosis, by means of an objective quantitative method and a clinical scale for the assessment of spasticity.
Methods

PATIENT SELECTION
Seventeen patients were entered into the study, but one patient was excluded from further analysis because the baseline severity of spasticity decreased during the study to below that stipulated in the protocol. There were 13 women and four men, mean age 43 (range 24-58) years. All patients had definite multiple sclerosis, diagnosed by clinical criteria and paraclinical investigations. Spasticity had been present for a mean of 70 (range 12-180) months and had been stable for a mean of 17 (range 2-48) months. Extensor spasticity reaching a minimum score of 2 on the Ashworth scale in at least one leg and remaining stable for at least one month was required as an entry criterion. All patients had a baseline score of either 2 or 3 on knee extensors, none had a score of 4, and none of them were bedridden. Patients receiving any drugs with antispastic action, those with significant systemic diseases, local complications, an exacerbation of the disease, or abnormalities in laboratory tests were excluded from the study.
EXPERIMENTAL PROCEDURE
The protocol was approved by the committee on medical ethics of Dundee General Hospitals, and informed consent was obtained from each patient before they entered the trial. Patients were allocated a treatment sequence according to a randomisation schedule based on a latin square design. Each patient received in a double blind, randomised, cross over design single doses of 2 mg, 4 mg and 8 mg of tizanidine and one dose of placebo on four separate days, allowing a wash out period of at least 72 hours between the different doses. Tizanidine and placebo tablets had the same appearance, and each dose contained the same number of tablets with the same appearance to maintain blindness.
The examination schedule and content as well as timing of meals were standardised for each patient and across the patients. The medication was taken with a glass of water between 8 00 and 9 00 am, 30 minutes before breakfast and after the baseline evaluations had been performed. An indwelling catheter was placed in the cubital vein 30 minutes before the daily baseline evaluations. Blood samples were taken at baseline, 15, and 30 minutes and 1, 1-5, 2, 2-5, 3, 4, 6, and 8 hours after dosing. Plasma tizanidine concentrations were analysed by a specific radioimmunoassay method with a sensitivity of 250 ng/l.
MEASUREMENT OF SKELETAL MUSCLE TONE
Each patient was given an initial screening assessment at which muscle tone was evaluated for both legs. Thereafter all measurements were performed on the leg that had the higher spasticity score at the knee extensors. The tone of the quadriceps muscle was measured by means of an electrogoniometer and applying the Wartenberg pendulum test.'2 The principle of this test is that the swing pattern of the lower leg, as it swings under the action of gravity, depends on the tone in the quadriceps muscle. A quantified version of the test was reintroduced by Bajd and Vodovnik"3 and is able to distinguish spasticity and rigidity.'4 The following procedure was used for taking a measurement: The patients lay on a couch with the lower legs hanging over the end. The examined leg was indirectly attached to an electrogoniometer (Penny and Giles, Type PGS) so as to measure the angle at the knee by the method described by Bajd and Vodovnik."3 The lower leg was lifted as near to the horizontal as possible without taking the upper leg off the couch. Having ensured that the leg was relaxed, the lower leg was then released and allowed to swing freely under gravity. The angle data were sampled for 10 seconds by a 286 PC microcomputer via a CED 1401 intelligent interface (Cambridge Electronic Design). Seven tests were taken at each assessment session. The first swing was for practice and it was not included in the analysis. Statistics of the assessment data were obtained by calculating the mean value of each variable from the next six tests. During the examination patients were distracted by music played through headphones to maximise muscle relaxation and to standardise experimental conditions. Goniometric assessments were performed at baseline immediately before drug intake and 30 minutes, 1, 1-5, 2, 3, 4, 6, and 8 hours after the drug intake.
Bajd and Vodovnik"3 have proposed that the best quantitative assessment of spasticity is made from the relaxation index, R2, and this has been confirmed by Brown et al. 14 This is the ratio of the amplitude of the first swing of the leg on release to the difference in angle between the start and final resting position (fig 1) . The relaxation index R2 was calculated with PC software. The log of the ratio R2 was used for the confirmatory data analysis. Further data were derived from the pendulum swing traces for descriptive and exploratory analysis. The additional measurements were the ratio Rl (the ratio of the amplitude of the first swing to the amplitude of first rebound swing), the maximum velocity on the first swing, the maximum velocity on the first rebound swing, the maximum acceleration on the first swing, and the maximum acceleration on the rebound swing.
Muscle tone was also assessed clinically with the Ashworth scale. ' Figure 1 gives examples of goniometric recordings before and after tizanidine. In the confirmatory analysis the logl0 of the difference between the R2 ratio at 1-5 hours and the R2 ratio at baseline for that day and a log transformation of the dose was examined by 4 8 regression analysis (F test). This analysis gave oseI2)mg) As well as the analysis of within patient correlations, between patient linear correlations between plasma concentrations and the differ-__-ence in R2 ratios between placebo v active treatment were also calculated. The analysis showed that 14 Figure 4 shows the m( plasma concentration curves at t] doses. In the exploratory data ana: statistical evaluation of dose-normal under the curve (AUC) and the n concentration (Cm.,) at the three dc examined gave results consistent wi pharmacokinetics in the dose range u variability in the peak plasma conce between patients given the same tizanidine was low (36% at 2 mg, 2 and 8 mg).
CORRELATION BETWEEN ASHWORTH S5 AND R2 RATIO
The mean change from baseline in i score two hours after medication was placebo, 29% for 2 mg, 34% for 4 38% for 8 mg. These mean changes, must be interpreted with caution f non-linear nature of the Ashworth se comparison of changes in the R2 vE concomitant changes in the Ashwoi for extensor muscles by means of patient rank correlation analysis shc nificant correlations between the two at all doses, indicating a strong withi linear correlation between the R2 I Ashworth score for extensor tone (S rank order correlation coefficients 0-001) for 2 mg; 0-431 (p = 0-009) f and 0-629 (p = 0-0001) for 8 mg). ' a between patient rank correlation showed that the changes in these two significantly correlated with each ot] dose levels. The number of significa lations increased dose dependently. ratio and Ashworth score were negatively correlated in both between and within patient correlation analysis-that is, the higher the R2 ratio, the lower the extensor tone on the Ashworth scale. Muscle strength, as measured by the BMRC scale did not show any detectable decrease in either extensor or flexor muscle strength at any time after any of the doses of tizanidine.
There was a mild decrease in blood pressure (mean 18 mm Hg systolic and 10 mm Hg diastolic pressure) and heart rate (5 beats/min), one to two hours after the 8 mg single dose of tizanidine. Adverse events appeared in a dose dependent manner. Drowsiness was the most frequent adverse event (one patient in the 2 mg, four patients in the 4 mg, nine patients in the 8 mg, and three patients in the placebo group), followed by dry mouth. All adverse events were rated mild to moderate, and there were no severe adverse events. Total number of adverse events as well as the sum of intensity scores peaked around two hours after drug administration, roughly corresponding to the time of maximum plasma concentration.
in patient Discussion ratio and The purpose of this study was to assess the )pearman relations between dose, plasma concentra-327 (p = tions, and antispastic effects of tizanidine. spastic muscle tone did not differ from placebo, so that unit doses higher than 2 mg are likely to be necessary in most patients. This study also showed a good correlation between the clinical scale (Ashworth scale) most often used to assess spasticity and the objective, quantitative measurement of muscle tone by an electrogoniometer. This finding is important as it suggests that used in a standard way (by the same investigator), the Ashworth scale can be reliably used to assess spasticity in large scale clinical studies in which the use of an electrogoniometer may not be possible. Electrogoniometric measurements, however, seemed to be more sensitive than the clinical assessment to the changes in muscle tone, so that small changes may not be detected by the Ashworth scale. The results also suggest that the electrogoniometer can be reliably used to provide quantitative assessment of muscle tone in spasticity.
At doses at which there was a clinically measurable decrease in spastic muscle tone with the Ashworth scale, no clinically detectable decrease in muscle strength was found on the BMRC scale. This suggests that the antispastic action of tizanidine is not associated with any undue muscle weakness. In fact, in some patients an antiparetic effect was associated with the antispastic effect of tizanidine.'0 It must be borne in mind, however, that the BMRC scale may not be sensitive enough to measure slight changes in muscle strength.
Single doses of tizanidine up to 8 mg were well tolerated. The adverse event profile did not differ from that known from previous experience.9 The most frequent adverse event was mild drowsiness. The frequency and severity of adverse events increased in a roughly dose dependent manner and peaked around the time of maximum plasma concentration. This suggests that adverse events may be related to peak plasma concentrations.
It is concluded that there is a linear relation between single doses, plasma concentrations, and antispastic effects of tizanidine in the 2-8 mg dose range. This relation is especially strong in within patient comparisons-that is, in a given patient the antispastic effect is closely related to plasma concentrations of tizanidine. The between patient correlations between plasma concentrations and antispastic effects seem to be less pronounced; thus a certain plasma concentration does not always lead to the same amount of muscle relaxation in all patients. Because a close within patient relation between dose, plasma concentration, and efficacy was found, the effective doses of tizanidine should be determined individually for each patient. The unit doses and dose intervals should be chosen so as to maintain an effective plasma concentration.
